QC-182

N/A

Report date: 2024/02/29 17:48:45
NME

Base Information

Drug NameQC-182
Drug Alias NameQC-182
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of Actionp300-CBP transcription factors degraders
Targetsp300-CBP transcription factors
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSchool Of Pharmacy, Fudan University
China Registration ClassN/A

Develop Information

Active CompaniesSchool Of Pharmacy, Fudan University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A